Latest

08.02.2022

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis®

Read Article
06.02.2022

Cellworks Singula Therapy Response Index (TRI) Predicts Clinical Outcomes For Esophageal Adenocarcinoma: MyCare-004

Read Article
06.02.2022

Predictions of Overall Survival And Progression-Free Survival For Therapeutic Interventions In Glioblastoma Multiforme

Read Article
04.14.2022

Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer

Read Article
04.13.2022

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

Read Article
12.23.2021

FDA Authorizes Merck’s Covid-19 Pill for At-Home Treatment

Read Article
12.20.2021

Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)

Read Article
12.20.2021

Behind a New Pill to Treat Covid: A Husband-and-Wife Team and a Hunch

Read Article
Up NextAbout Us